Skip to Content
Merck

L5413

Formyl-[D-Trp6]-LH-RH Fragment 2-10

>97% (HPLC)

Synonym(s):

Formyl-Triptorelin 2-10

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C60H77N17O12
Molecular Weight:
1228.36
NACRES:
NA.32
PubChem Substance ID:
329817624
UNSPSC Code:
12352203
MDL number:
MFCD03093472

Product Name

Formyl-[D-Trp6]-LH-RH Fragment 2-10, >97% (HPLC)

InChI

1S/C60H77N17O12/c1-33(2)21-45(53(83)71-43(13-7-19-65-60(62)63)59(89)77-20-8-14-50(77)58(88)68-29-51(61)81)72-55(85)47(23-35-26-66-41-11-5-3-9-39(35)41)75-54(84)46(22-34-15-17-38(80)18-16-34)73-57(87)49(30-78)76-56(86)48(24-36-27-67-42-12-6-4-10-40(36)42)74-52(82)44(70-32-79)25-37-28-64-31-69-37/h3-6,9-12,15-18,26-28,31-33,43-50,66-67,78,80H,7-8,13-14,19-25,29-30H2,1-2H3,(H2,61,81)(H,64,69)(H,68,88)(H,70,79)(H,71,83)(H,72,85)(H,73,87)(H,74,82)(H,75,84)(H,76,86)(H4,62,63,65)/t43-,44-,45-,46-,47+,48-,49-,50-/m0/s1

SMILES string

CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6c[nH]cn6)NC=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N7CCC[C@H]7C(=O)NCC(N)=O

InChI key

ZZPMMEBSDBNQDQ-NTXUYPKOSA-N

assay

>97% (HPLC)

UniProt accession no.

P13562

storage temp.

−20°C

Quality Level

100

Gene Information

mouse ... Gnrh1(14714)

Biochem/physiol Actions

Formyl-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 (Formyl-[D-Trp6]-LH-RH Fragment 2-10) is a peptide from GnRH (gonadotropin-releasing hormone) agonist, triptorelin. GnRH (Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which is also referred as LHRH (luteinizing hormone-releasing hormone) or gonadorelin, is crucial for mammalian reproduction and is released from hypothalamic neurons. It is responsible for the secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary glands. Mutations in GnRH are associated with normosmic congenital hypogonadotropic hypogonadism. Application of triptorelin suppresses premature LH surge in IVF (in vitro fertilization). Additionally, triptorelin-mediated ovarian suppression in premenopausal women, undergoing chemotherapy for breast cancer, decreases chances of chemotherapy-associated early menopause.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
081K1782

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lucia Del Mastro et al.
JAMA, 306(3), 269-276 (2011-07-21)
Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. To determine the effect of the temporary ovarian suppression obtained by
P C Lindsay et al.
Fertility and sterility, 65(2), 342-348 (1996-02-01)
To assess whether tibolone can prevent the bone loss and symptomatic side effects normally associated with GnRH agonist (GnRH-a) use and whether tibolone modifies the effect of GnRH-a on endometriosis. Prospective, double-blind, placebo-controlled, group comparative study. Gynecological research unit in
R M Janssens et al.
Human reproduction (Oxford, England), 15(11), 2333-2340 (2000-11-01)
Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the
Indira Nederpelt et al.
British journal of pharmacology, 173(1), 128-141 (2015-09-24)
Drug-target residence time is an important, yet often overlooked, parameter in drug discovery. Multiple studies have proposed an increased residence time to be beneficial for improved drug efficacy and/or longer duration of action. Currently, there are many drugs on the
Luigi Maione et al.
PloS one, 8(7), e69616-e69616 (2013-08-13)
Normosmic congenital hypogonadotropic hypogonadism (nCHH) is a rare reproductive disease leading to lack of puberty and infertility. Loss-of-function mutations of GNRH1 gene are a very rare cause of autosomal recessive nCHH. R31C GNRH1 is the only missense mutation that affects
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service